Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists
Abstract
In 2023, international consensus recommendations suggested the use of prolonged‐infusion beta‐lactam antibiotics over short‐infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused update re‐evaluates the efficacy of prolonged versus short infusion among severely ill adult patients. The original Population, Intervention, Comparator, and Outcome (PICO) question VII was separated into two questions addressing mortality (VIIa) and clinical cure (VIIb). Methods used for study identification, screening, and evidence grading were consistent with the original guideline, with the addition of Bayesian meta‐analyses. A total of 28 RCTs evaluating mortality in severely ill adults were analyzed, with pooled estimates favoring prolonged infusion (RR 0.91; 95% confidence interval 0.85 to 0.97), supported by Bayesian analyses demonstrating a 98.76% posterior probability of benefit. Across 21 RCTs evaluating clinical cure, prolonged infusion improved outcomes compared with short infusion (RR 1.11; 95% confidence interval 1.06 to 1.17), supported by Bayesian analyses demonstrating a 99.97% posterior probability of benefit. Certainty of evidence was strengthened to moderate for mortality and low for clinical cure. Consistent with the original recommendation (PICO X), subgroup analyses evaluating loading doses suggested improved outcomes when a loading dose is used before continuous infusion. Overall, the cumulative evidence reinforces and strengthens the recommendation for use of prolonged‐infusion beta‐lactam therapy in severely ill adult patients to improve survival and clinical cure. Continued use of loading doses when initiating continuous‐infusion therapy is suggested. Future research should identify subpopulations most likely to benefit, clarify optimal prolonged‐infusion strategies, and define the role of therapeutic drug monitoring.
Related
- Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti‐Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists
- Handheld Ultrasound: Technical Review and International Expert Consensus Recommendations
- Concordance of next-generation sequencing and conventional microbiology for pathogen detection and antimicrobial resistance prediction in pneumonia
- Comparative Microbiology and Antimicrobial Resistance of Bacterial Isolates from Wound Specimens at Tertiary-Care Centres in Ghana and Germany: A Retrospective Two-Centre Study.
- Reported practice patterns in the use of local antibiotics for fracture-related infection among SICOT respondents: an international survey.
BibTeX
@article{hong2026focused,
title = {{Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists}},
author = {Lisa Hong and Alireza Fakhriravari and Marta Ulldemolins and Jason A. Roberts and Robert Bonomo and Marc Scheetz},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
month = aug,
doi = {10.1002/phar.70188},
url = {https://hal.science/hal-05825324v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists
AU - Lisa Hong
AU - Alireza Fakhriravari
AU - Marta Ulldemolins
AU - Jason A. Roberts
AU - Robert Bonomo
AU - Marc Scheetz
PY - 2026
DA - 2026/08/14
JO - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
DO - 10.1002/phar.70188
UR - https://hal.science/hal-05825324v1
AB - In 2023, international consensus recommendations suggested the use of prolonged‐infusion beta‐lactam antibiotics over short‐infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused update re‐evaluates the efficacy of prolonged versus short infusion among severely ill adult patients. The original Population, Intervention, Comparator, and Outcome (PICO) question VII was separated into two questions addressing mortality (VIIa) and clinical cure (VIIb). Methods used for study identification, screening, and evidence grading were consistent with the original guideline, with the addition of Bayesian meta‐analyses. A total of 28 RCTs evaluating mortality in severely ill adults were analyzed, with pooled estimates favoring prolonged infusion (RR 0.91; 95% confidence interval 0.85 to 0.97), supported by Bayesian analyses demonstrating a 98.76% posterior probability of benefit. Across 21 RCTs evaluating clinical cure, prolonged infusion improved outcomes compared with short infusion (RR 1.11; 95% confidence interval 1.06 to 1.17), supported by Bayesian analyses demonstrating a 99.97% posterior probability of benefit. Certainty of evidence was strengthened to moderate for mortality and low for clinical cure. Consistent with the original recommendation (PICO X), subgroup analyses evaluating loading doses suggested improved outcomes when a loading dose is used before continuous infusion. Overall, the cumulative evidence reinforces and strengthens the recommendation for use of prolonged‐infusion beta‐lactam therapy in severely ill adult patients to improve survival and clinical cure. Continued use of loading doses when initiating continuous‐infusion therapy is suggested. Future research should identify subpopulations most likely to benefit, clarify optimal prolonged‐infusion strategies, and define the role of therapeutic drug monitoring.
SN - 0277-0008
ER -